This study evaluates the therapeutic potential of ANV600, a PD-1-directed IL-2Rβγ agonist designed to selectively expand tumor antigen-specific T cells. The model allowed in vivo validation of ANV600's ability to activate and expand antigen-specific T cells without triggering Treg-mediated immune suppression.
Demonstrated that ANV600 selectively activates effector T cells, expands tumor-reactive clones, and enhances the efficacy of PD-1 checkpoint inhibition in solid tumors.
genO-hPD-1 Knockin mouse model developed by genOway, enabling selective engagement of the human PD-1 extracellular domain in vivo.
Cancer immunotherapy, PD-1 checkpoint inhibition, IL-2 pathway, T cell expansion
Humanized Knockin, PD-1, Immune checkpoint, T cell immunotherapy
From model design to experimental results
Featured in 600+ scientific articles
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Generated with biopharma partners and in-house
and guaranteed freedom to operate
Models with certified health status from professional breeders in US and Europe
